Insuman Comb 30 (Insulin Human)

Insulin human binds to insulin receptors on muscle, fat and liver cells, activating intracellular signaling that promotes glucose uptake via GLUT‑4 transporters and suppresses hepatic glucose production. This dual action reduces circulating blood glucose and facilitates storage of glucose as glycogen, thereby normalizing glycemic levels.

The dose of Insuman Comb 30 is individualized and set by the prescribing healthcare professional based on factors such as the patient’s age, weight, blood glucose targets, diet, and overall health. Patients should follow the prescriber’s instructions and regularly monitor their glucose to ensure appropriate dosing.

Insuman Comb 30 is classified as pregnancy category B, indicating that animal studies have not shown risk to the fetus and there are no adequate human studies. It may be used during pregnancy or lactation when clearly needed, but the decision should be made by a healthcare provider weighing potential benefits and risks.

To order Insuman Comb 30, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide. After the request, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details—including cold‑chain handling if needed—and assist with import documentation.

Insuman Comb 30 combines rapid‑acting and intermediate‑acting insulin in a single formulation, offering a convenient mixed‑dose option. Compared with basal‑only insulins, it provides prandial coverage without separate injections, while differing from premixed analog insulins that use modified insulin analogs. Choice depends on patient preference, glycemic patterns and clinician judgment.

Insuman Comb 30 should be stored at 2‑8 °C (refrigerated) and protected from light. Do not freeze or shake the vial. Once opened, it may be kept at room temperature (up to 25 °C) for a limited period as specified in the product labeling, but must be discarded after the recommended in‑use time.

Insuman Comb 30 is administered by subcutaneous injection into the abdomen, thigh or upper arm. The injection should be given using a sterile needle, rotating sites to reduce lipodystrophy risk. The prescriber determines the injection schedule—typically once or twice daily—based on the patient’s glycemic targets and lifestyle.

The most serious risks include severe hypoglycemia, which can lead to loss of consciousness or seizures, and rare allergic reactions such as anaphylaxis. Patients should be educated to recognize early hypoglycemia signs, carry fast‑acting carbohydrates, and seek immediate medical attention if a serious reaction occurs.

Insuman Comb 30 is contraindicated in individuals with a known hypersensitivity to insulin human or any excipients in the formulation. It should also be avoided in patients experiencing hypoglycemia until the condition is resolved. Clinicians must assess each patient’s medical history before initiating therapy.